SCHEMBL4785764

SCHEMBL4785764

COc1cccc(C2SCCCS2)c1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.49
HTR2C P28335 4/20 0.49
HTR2A P28223 2/20 0.46
HTR2B P41595 2/20 0.46
GID4 Q8IVV7 1/20 0.46
KDM1A O60341 1/20 0.43
RCOR1 Q9UKL0 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.43
DRD2 P14416 2/20 0.43
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16597324 0.93 HTR2C (0.51) TSHRHTR2CHTR2AHTR2BGID4
SCHEMBL4523793 0.91 TSHR (0.44) TSHRHTR2CKDM1AGAA
SCHEMBL9778608 0.89 LTA4H (0.44) TSHRHTR2CHTR2AHTR2BGID4
SCHEMBL9778784 0.83 NPC1 (0.53) NPC1
SCHEMBL16597328 0.82 TP53 (0.45) TSHRKDM4ENPC1GAA
SCHEMBL4825695 0.82 TSHR (0.46) TSHRMEN1GAAKMT2A
SCHEMBL11086094 0.81 TSHR (0.51) TSHRKDM4EMEN1KMT2A
SCHEMBL29576576 0.81 TSHR (0.51) TSHRKDM4EMEN1KMT2A
SCHEMBL9778614 0.80 SLC5A2 (0.45) TSHRMEN1GAAKMT2ADRD2
SCHEMBL1344540 0.78 TSHR (0.50) TSHRHTR2CKDM1AKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117603183-A 1,3-dithiane modified alpha, beta-unsaturated derivative and preparation method thereof 兰州大学 2024-02-27 CN disclosed
CN-117069645-A Tryptophan and C2 alkylation modification method for tryptophan-containing polypeptide 兰州大学 2023-11-17 CN disclosed
EP-3049401-B1 POLYMER-FIXED DERIVATIVES OF DITHIOLANE OR DITHIANE KARLSRUHER INST TECHNOLOGIE (DE) 2018-11-07 EP disclosed
US-9518039-B2 Polymer-fixed derivatives of dithiolane or dithiane KARLSRUHER INSTITUT FUER TECHNOLOGIE (DE) 2016-12-13 US disclosed
US-20160229832-A1 POLYMER-FIXED DERIVATIVES OF DITHIOLANE OR DITHIANE KARLSRUHER INSTITUT FUER TECHNOLOGIE (DE) 2016-08-11 US disclosed
US-20080176862-A1 Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors ASTRAZENECA AB (SE) 2008-07-24 US disclosed
US-20080176862-A1 Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors ASTRAZENECA AB (SE) 2008-07-24 US disclosed
US-20080176862-A1 Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors ASTRAZENECA AB (SE) 2008-07-24 US disclosed
WO-2008076046-A1 NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES ASTRAZENECA AB (SE) 2008-06-26 WO disclosed
WO-2008076046-A1 NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES ASTRAZENECA AB (SE) 2008-06-26 WO disclosed
US-5063197-A Aromatic compound MITSUBISHI PAPER MILLS LIMITED (JP) 1991-11-05 US disclosed
US-4127588-A Sulphur containing derivatives HOFFMANN-LA ROCHE INC. (US) 1978-11-28 US disclosed
US-4073797-A CORONARY DILATOR HOFFMANN-LA ROCHE INC. (US) 1978-02-14 US disclosed
US-4003914-A DITHIANE AND DISULFONE CORONARY DILATING AGENTS HOFFMANN-LA ROCHE INC. (US) 1977-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176862-A1 Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors BACE1, BACE2, PSEN1 TSHR 4849/4885HTR2C 2505/4885HTR2A 3231/4885
US-20160229832-A1 POLYMER-FIXED DERIVATIVES OF DITHIOLANE OR DITHIANE TCP1, ALG1, DDAH1 TSHR 3429/4885HTR2C 4818/4885HTR2A 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.